Why Edibles Hit Different
How first-pass metabolism and 11-hydroxy-THC make oral cannabis distinct from inhalation.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Edibles and smoking take completely different routes through your body. Smoking hits fast because THC goes straight to your lungs and blood. Eating puts THC through your liver first, where it converts to 11-hydroxy-THC—a metabolite that is itself psychoactive. This detour is why edibles are slower, longer-lasting, and much harder to dose predictably. The hype about edibles being '4× stronger' is folklore, but the practical differences are real and matter for safety.
Not medical advice
This article summarizes published pharmacology and clinical data on oral cannabis. It is not medical advice, not a dosing recommendation, and not a substitute for talking to a clinician—especially if you take other medications, are pregnant, have a cardiac or psychiatric history, or are considering cannabis for a medical condition. Laws vary by jurisdiction.
Plain-language summary
When you smoke or vape THC, it reaches your lungs, enters the blood, and crosses into the brain within minutes. When you eat THC, it travels from your gut to your liver before entering the bloodstream and brain—a detour that takes roughly 1–2 hours and fundamentally changes how the drug behaves.
That liver detour is the key: your body converts a significant fraction of THC into 11-hydroxy-THC (11-OH-THC), a compound that is itself psychoactive and crosses the blood-brain barrier efficiently [1][2] Strong evidence.
The practical consequences:
- Slow onset (typically 30–120 minutes) [3][4] Strong evidence
- Delayed peak (2–4 hours) and long tail (often 6–8 hours or longer) [3][4] Strong evidence
- Highly variable absorption between individuals and depending on what you ate, your metabolism, and gut health [1][2] Strong evidence
- Easy to overshoot by taking more before the first dose takes effect [5] Strong evidence
The popular claim that edibles are "4 times stronger mg-for-mg" is folklore. The reality is more nuanced: they are slower, longer-acting, more unpredictable, and often feel qualitatively different—but whether 11-OH-THC is definitively more potent than THC in humans at typical doses remains incompletely settled Disputed.
What probably works (strong evidence)
1. Oral THC has delayed onset and prolonged duration compared to inhaled cannabis. Controlled pharmacokinetic studies consistently show that plasma THC peaks within ~10 minutes after smoking but 1–3 hours after oral dosing [1][2][3] Strong evidence. The blood concentration of THC remains elevated for much longer with oral administration.
2. First-pass hepatic metabolism produces substantial amounts of 11-hydroxy-THC. After oral dosing, plasma 11-OH-THC concentrations are typically equal to or exceed THC concentrations; after smoking, 11-OH-THC is much lower [1][2] Strong evidence. This occurs because your liver metabolizes THC as it enters the bloodstream from the gut.
3. 11-hydroxy-THC is psychoactive in humans. Direct intravenous administration of 11-OH-THC produces cannabis-like subjective effects including euphoria, altered perception, and intoxication [6] Strong evidence. This metabolite contributes meaningfully to the subjective experience of oral cannabis.
4. Overconsumption of edibles drives emergency department visits. Population data from Colorado showed a disproportionate share of cannabis-related emergency visits came from edibles relative to their market share, often involving accidental overdose, acute anxiety, and cardiovascular symptoms [5] Strong evidence. The delayed onset is a key contributor: users redose before recognizing they are already intoxicated.
5. Start-low-go-slow harm-reduction guidance reduces adverse events. This is the consensus recommendation from public health agencies in legal-cannabis jurisdictions and is supported by the overdose literature [7] Strong evidence.
What might work (weak or mixed evidence)
11-hydroxy-THC is substantially more potent than THC. The often-cited claim that 11-OH-THC is 1.5–4 times more potent than THC derives from older animal studies and a single seminal human study [6] Weak / limited. It is reasonable to infer that 11-OH-THC has enhanced CB1 receptor affinity and blood-brain penetration, but the precise potency ratio in humans at realistic edible doses is not well established. Published human trials do not directly compare equipotent doses of THC vs. 11-OH-THC Disputed.
Eating a high-fat meal with your edible increases THC absorption. A controlled human study found that a high-fat meal increased CBD (cannabidiol) oral bioavailability roughly 4-fold [8] Weak / limited. Analogous rigorous data specifically for THC edibles in humans are limited. The biological mechanism—improved lipophilic drug solubilization—is sound, but whether this applies uniformly to finished edible products or is clinically relevant at therapeutic doses remains uncertain.
Sublingual or buccal absorption can bypass first-pass metabolism. If a tincture or spray is genuinely retained under the tongue, some absorption through oral mucosa is pharmacologically plausible and avoids liver metabolism [9] Weak / limited. However, most "sublingual" products are swallowed, leading to standard first-pass metabolism and behaving like conventional edibles.
Tolerance to the subjective effects of edibles develops similarly to smoked cannabis. This is likely based on CB1 receptor downregulation observed across cannabis routes Weak / limited. Head-to-head studies directly comparing tolerance development across inhaled vs. oral routes are sparse.
What doesn't work / folklore
- "10 mg of THC is 10 mg of THC." Bioavailability of oral THC varies widely—roughly 4–20% across individuals—owing to genetic differences in liver metabolism, meal composition, gut transit, and other factors [1][2] Strong evidence. The same product in two different people will produce vastly different blood levels and effects.
- "Indica edibles will couch-lock you; sativa edibles will energize you." The indica vs. sativa label does not reliably predict subjective effects, and this distinction becomes even less meaningful after liver metabolism dramatically alters the cannabinoid profile Disputed. See Indica vs Sativa: The Myth for details.
- "If you don't feel it after an hour, take more." This is the single most common path to accidental overconsumption and acute toxicity. Median onset is ~60–90 minutes, with peak effects at 2–4 hours [3][4] Strong evidence. Redosing before peak is a major driver of emergency presentations.
- "Edibles don't show up on drug tests." They absolutely do—often for longer than smoked cannabis, because 11-OH-THC and its glucuronide metabolite (THC-COOH) circulate and are excreted slowly Strong evidence. Oral cannabis can extend detection windows.
What we don't know
- Precise in vivo potency of 11-OH-THC vs. THC in humans at edible-relevant doses. No published randomized controlled trial has directly compared equal doses of pure THC vs. pure 11-OH-THC administered orally to the same subjects, measured both pharmacokinetically and subjectively.
- The relative contribution of genetic polymorphisms, meal composition, and gut physiology to inter-individual bioavailability variance. Variants in CYP2C9, CYP3A4, and other metabolizing enzymes likely play a role, but systematic human data partitioning these factors are absent.
- Whether minor cannabinoids and terpenes survive cooking and first-pass metabolism in pharmacologically meaningful amounts. Claims that "the entourage effect" explains why edibles feel different rest primarily on in vitro and animal data; human evidence is minimal Weak / limited.
- Long-term health effects of frequent high-dose edible use specifically, isolated from effects of smoked cannabis. Most longitudinal cannabis studies do not distinguish by route or edible type.
Comparison with standard treatments and other routes
Approved oral cannabinoid medications:
Dronabinol (synthetic THC capsule, FDA-approved for chemotherapy-induced nausea and AIDS-related anorexia) undergoes identical first-pass metabolism to edibles: slow onset (~1–2 hours), substantial 11-OH-THC production, and long duration [10] Strong evidence.
Nabiximols (Sativex, THC:CBD oromucosal spray, approved in some countries) was partly designed to reduce first-pass metabolism by absorbing through oral mucosa, yielding faster and more predictable onset than swallowed products [11] Strong evidence.
vs. Inhaled cannabis (smoking or vaping): faster onset (minutes), easier self-titration, shorter duration (1–3 hours), and minimal 11-OH-THC exposure. The trade-off is respiratory irritation with combustion and tar exposure.
vs. Standard pharmacotherapy (e.g., ondansetron for nausea, zolpidem for sleep, gabapentin for neuropathic pain): approved medications generally have larger, more specific evidence bases for defined conditions. Edibles may be considered adjuncts in some patients but should not be assumed equivalent to or a replacement for first-line pharmacological treatment Weak / limited.
Risks
- Acute overconsumption: anxiety, panic attacks, tachycardia, vomiting, dissociation, and rarely transient psychotic-like symptoms. Driven primarily by the onset–peak lag and user redosing [5] Strong evidence.
- Pediatric exposures: edibles designed to resemble candy or snacks pose a documented poisoning risk to young children; cases have risen sharply in legal markets [12] Strong evidence.
- Cardiovascular events: case reports and observational data link acute high-dose THC to myocardial infarction and arrhythmia in susceptible individuals, particularly those with underlying cardiac risk Weak / limited.
- Drug interactions: both CBD and THC inhibit CYP3A4, CYP2C9, and other cytochrome P450 enzymes, potentially raising concentrations of warfarin, clobazam, tacrolimus, and other narrow-therapeutic-index drugs Strong evidence.
- Cannabinoid hyperemesis syndrome: chronic heavy cannabis use can trigger this syndrome (recurrent nausea, abdominal pain, compulsive hot bathing) regardless of route Strong evidence.
- Driving impairment: the prolonged duration of edibles means impairment lasts longer than after inhaled cannabis, extending the risk window Strong evidence.
If you are using edibles for medical purposes, discuss your full medication list and cannabis use with a clinician familiar with cannabis pharmacology.
Sources
- Peer-reviewed Huestis MA. Human cannabinoid pharmacokinetics. Chemistry & Biodiversity. 2007;4(8):1770-1804.
- Peer-reviewed Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics. 2003;42(4):327-360.
- Peer-reviewed Newmeyer MN, Swortwood MJ, Barnes AJ, Abulseoud OA, Scheidweiler KB, Huestis MA. Free and glucuronide whole blood cannabinoids' pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users. Clinical Chemistry. 2016;62(12):1579-1592.
- Peer-reviewed Vandrey R, Herrmann ES, Mitchell JM, et al. Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes. Journal of Analytical Toxicology. 2017;41(2):83-99.
- Peer-reviewed Monte AA, Shelton SK, Mills E, et al. Acute illness associated with cannabis use, by route of exposure: an observational study. Annals of Internal Medicine. 2019;170(8):531-537.
- Peer-reviewed Lemberger L, Crabtree RE, Rowe HM. 11-hydroxy-Δ9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science. 1972;177(4043):62-64.
- Government Colorado Department of Public Health and Environment. Marijuana Health Information & Public Education: Edibles and Dosing Guidance.
- Peer-reviewed Birnbaum AK, Karanam A, Marino SE, et al. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia. 2019;60(8):1586-1592.
- Peer-reviewed Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral delta-9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clinical Chemistry. 2011;57(1):66-75.
- Government U.S. Food and Drug Administration. Marinol (dronabinol) capsules—prescribing information.
- Peer-reviewed Russo EB. Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management. 2008;4(1):245-259.
- Peer-reviewed Tweet MS, Nemanich A, Wahl M. Pediatric edible cannabis exposures and acute toxicity: 2017–2021. Pediatrics. 2023;151(2):e2022057761.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis and Sleep — Evidence-based overview of cannabis, THC, and CBD for sleep onset and insomnia.
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...
- Why Some People Don't Feel Edibles — Why oral THC fails for some users and what the evidence says.